# US 2020/0268801 A1 · Biochemical and biomechanical conditioning for enhancing personalized mesenchymal stem cell therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0268801 A1
- Document ID: US20200268801A1
- Status: Published application
- Kind: A1
- Application number: 16/650,195
- Filed: 2018-09-26
- Published: 2020-08-27
- Earliest claimed: 2017-09-26
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, the University of Texas System
- Inventors: Aaron B. BAKER; Jason LEE
- Web page: https://patentgrep.com/patent/US20200268801A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C12N 5/0668: {Mesenchymal stem cells from other natural sources}
- C12N 5/069: {Vascular Endothelial cells}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2503/00: Use of cells in diagnostics
- C12N 2527/00: Culture process characterised by the use of mechanical forces, e.g. strain, vibration
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A high-throughput screening system is provided for optimizing the conditioning of patient-specific mesenchymal stem cells using a combinatorial set of biochemical factors, pharmacological inhibitors, and biomechanical forces. Also provided are generalized conditions for performing such conditioning. Cells made by these methods are also provided, in addition to cells having a mixed N endothelial cell/pericyte phenotype. These cells produce angiogenic growth factors and induce vascularization following implantation.

## Claims

### Claim 1

A cell comprising both an endothelial phenotype and a pericyte phenotype.

### Claim 2 (depends on 1)

The cell of claim 1, wherein the phenotype is characterized by the expression of PECAM-1, CD105, VECad, CD146, Nestin, and PDGFRβ.

### Claim 3 (depends on 1)

The cell of claim 1, wherein the cell is not genetically modified.

### Claim 4 (depends on 1)

The cell of claim 1, wherein the pericyte phenotype is a type 2 pericyte phenotype.

### Claim 5 (depends on 4)

The cell of claim 4, wherein the cell expresses NG2.

### Claim 6 (depends on 1)

The cell of claim 1, wherein the cell has increased YAP/TAZ activation and increased SMAD2/3 activation.

### Claim 7

A method of enhancing the combined pericyte/endothelial character of mesenchymal stem cells (MSCs), the method comprising:
(a) obtaining a starting population of mesenchymal stem cells;
(b) culturing the mesenchymal stem cells on a flexible surface that allows cell adhesion; and
(c) applying a controlled shear stress/mechanical stretch to the mesenchymal stem cells with a force sufficient to produce a conditioned composition comprising cells having a combined pericyte/endothelial character.

### Claim 8 (depends on 7)

The method of claim 7, further comprising (d) incubating the mesenchymal stem cells with at least one pharmacological agent that inhibits EGFR signaling.

### Claim 9 (depends on 8)

The method of claim 8, wherein the agent inhibits either EGFR/ErbB signaling or EGFR/PKC signaling.

### Claim 10 (depends on 8)

The method of claim 8, wherein the agent enhances Smad2/3 and/or Hippo pathway activation.

### Claim 11 (depends on 8)

The method of claim 8, wherein the agent is a kinase inhibitor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the agent is an EGFR/Erb-2/4 inhibitor.

### Claim 13 (depends on 11)

The method of claim 11, wherein the agent is a PKCβII/EGFR inhibitor.

### Claim 14 (depends on 7)

The method of claim 7, further comprising (d) incubating the mesenchymal stem cells with at least one biochemical agent.

### Claim 15 (depends on 14)

The method of claim 14, wherein the biochemical agent is TGFβ.

### Claim 16 (depends on 7)

The method of claim 7, wherein the method produces MSCs having enhanced angiogenic potential.

### Claim 17 (depends on 7)

The method of claim 7, wherein the shear stress/mechanical stretch is generated using a true linear motor.

### Claim 18 (depends on 7)

The method of claim 7, wherein the shear stress/mechanical stretch is applied using a waveform.

### Claim 19 (depends on 18)

The method of claim 18, wherein the waveform is a dynamic mechanical loading waveform.

### Claim 20 (depends on 19)

The method of claim 19, wherein the dynamic mechanical loading waveform is a brachial waveform.

### Claim 21 (depends on 18)

The method of claim 18, wherein the waveform is a sine waveform.

### Claim 22 (depends on 7)

The method of claim 7, wherein the dynamic mechanical loading waveform has a frequency of 0.1 Hz-1.00 Hz.

### Claim 23 (depends on 7)

The method of claim 7, wherein the dynamic mechanical loading waveform has a magnitude of strain of 0.1% to 17.5%.

### Claim 24 (depends on 7)

The method of claim 7, wherein the dynamic mechanical loading waveform has a magnitude of 7.5% strain and a frequency of 0.1 Hz.

### Claim 25 (depends on 7)

The method of claim 7, wherein obtaining a starting population of mesenchymal stem cells comprises harvesting mesenchymal stem cells from the bone marrow or adipose tissue of a patient.

### Claim 26 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A composition of mesenchymal stem cells (MSCs) having a combined pericyte/endothelial phenotype produced by the method of any one of claims 7-25.

### Claim 27 (depends on 26)

The composition of claim 26, wherein the cells are not genetically modified.

### Claim 28 (depends on 26)

The composition of claim 26, wherein the pericyte phenotype is a type 2 pericyte phenotype.

### Claim 29 (depends on 26)

The composition of claim 26, wherein the cells express NG2.

### Claim 30 (depends on 26)

The composition of claim 26, wherein the cells can form myotubes.

### Claim 31 (depends on 26)

The composition of claim 26, wherein the cells have increased YAP/TAZ activation and increased SMAD2/3 activation.

### Claim 32 (depends on 26)

The composition of claim 26, wherein the cells have increased expression of endothelial markers and increased expression of pericyte markers.

### Claim 33 (depends on 32)

The composition of claim 32, wherein the endothelial markers comprise PECAM-1, CD105, and VECad.

### Claim 34 (depends on 32)

The composition of claim 32, wherein the pericyte markers comprise CD146, Nestin, PDGFRβ.

### Claim 35 (depends on 26)

The composition of claim 26, wherein the cells produce pro-angiogenic paracrine factors.

### Claim 36 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

A method of treating a patient in need thereof comprising administering a therapeutically effective amount of a composition of any one of claims 26-35 to the patient.

### Claim 37 (depends on 36)

The method of claim 36, wherein the patient has a cardiovascular disease, is receiving vascular grafts, has ischemia, is wound healing, has peripheral ischemia, or has peripheral vascular disease.

### Claim 38 (depends on 36)

The method of claim 36, wherein administering comprises injecting or implanting the cells into the patient.

### Claim 39

A method for identifying conditions for enhancing mesenchymal stem cell (MSC) therapies for a patient, the method comprising:
(a) obtaining from the patient a starting population of mesenchymal stem cells (MSCs);
(b) preparing multiple, separate cultures of the patient's MSCs on flexible surfaces that allow cell adhesion;
(c) applying a variety of controlled shear stresses/mechanical stretches to each of the MSCs; and
(d) screening the cultured cells for markers of a combined pericyte/endothelial cell phenotype, thereby identifying conditions for enhancing MSC therapies for the patient.

### Claim 40 (depends on 39)

The method of claim 39, further comprising (c1) incubating each of the cultures with at least one pharmacological agent that inhibits EGFR signaling.

### Claim 41 (depends on 40)

The method of claim 40, wherein the agent inhibits either EGFR/ErbB signaling or EGFR/PKC signaling.

### Claim 42 (depends on 40)

The method of claim 40, wherein the agent enhances Smad2/3 and/or Hippo pathway activation.

### Claim 43 (depends on 40)

The method of claim 40, wherein the agent is a kinase inhibitor.

### Claim 44 (depends on 43)

The method of claim 43, wherein the agent is an EGFR/Erb-2/4 inhibitor.

### Claim 45 (depends on 43)

The method of claim 43, wherein the agent is a PKCβII/EGFR inhibitor.

### Claim 46 (depends on 39)

The method of claim 39, further comprising (c1) incubating each of the cultures with at least one biochemical agent.

### Claim 47 (depends on 46)

The method of claim 46, wherein the biochemical agent is TGFβ.

### Claim 48 (depends on 39)

The method of claim 39, wherein the method identifies conditions for producing MSCs having enhanced angiogenic potential.

### Claim 49 (depends on 39)

The method of claim 39, wherein the shear stress/mechanical stretch is generated using a true linear motor.

### Claim 50 (depends on 39)

The method of claim 39, wherein the shear stress/mechanical stretch is applied using a waveform.

### Claim 51 (depends on 50)

The method of claim 50, wherein the waveform is a dynamic mechanical loading waveform.

### Claim 52 (depends on 51)

The method of claim 51, wherein the dynamic mechanical loading waveform is a brachial waveform.

### Claim 53 (depends on 50)

The method of claim 50, wherein the waveform is a sine waveform.

### Claim 54 (depends on 39)

The method of claim 39, wherein the dynamic mechanical loading waveform has a frequency of 0.1 Hz-1.00 Hz.

### Claim 55 (depends on 39)

The method of claim 39, wherein the dynamic mechanical loading waveform has a magnitude of strain of 0.1% to 17.5%.

### Claim 56 (depends on 39)

The method of claim 39, wherein obtaining a starting population of mesenchymal stem cells comprises harvesting mesenchymal stem cells from the bone marrow or adipose tissue of a patient.

### Claim 57 (depends on 39)

The method of claim 39, wherein the markers of a combined pericyte/endothelial cell phenotype comprise nuclear localization of YAP/TAZ, phosphorylation of SMAD2/3, nuclear localization of SMAD2/3, and increased expression of PECAM-1.

### Claim 58 (depends on 39)

The method of claim 39, wherein the method identifies conditions that increase the regenerative capacity of the patient's MSCs.

### Claim 59 (depends on 39)

The method of claim 39, wherein at least 10 individual culture conditions are tested simultaneously.

### Claim 60 (depends on 59)

The method of claim 59, wherein at least 100 individual culture conditions are tested simultaneously.

### Claim 61 (depends on 39)

The method of claim 39, further comprising:
(e) obtaining from the patient a starting population of mesenchymal stem cells (MSCs);
(f) culturing the MSCs on a flexible surface that allows cell adhesion; and
(g) applying the conditions identified following step (d) to the MSCs, thereby producing a therapeutically effective amount of MSCs having a combined pericyte/endothelial character.

### Claim 62 (depends on 61)

The method of claim 61, further comprising administering the conditioned MSCs to the patient.

### Claim 63 (depends on 61)

A composition of mesenchymal stem cells (MSCs) having a combined pericyte/endothelial phenotype produced by the method of claim 61.

### Claim 64 (depends on 63)

The composition of claim 63, wherein the cells are not genetically modified.

### Claim 65 (depends on 63)

The composition of claim 63, wherein the pericyte phenotype is a type 2 pericyte phenotype.

### Claim 66 (depends on 63)

The composition of claim 63, wherein the cells express NG2.

### Claim 67 (depends on 63)

The composition of claim 63, wherein the cells can form myotubes or endothelial-like tubes.

### Claim 68 (depends on 63)

The composition of claim 63, wherein the cells have increased YAP/TAZ activation and increased SMAD2/3 activation.

### Claim 69 (depends on 63)

The composition of claim 63, wherein the cells have increased expression of endothelial markers and increased expression of pericyte markers.

### Claim 70 (depends on 69)

The composition of claim 69, wherein the endothelial markers comprise PECAM-1, CD105, and VECad.

### Claim 71 (depends on 69)

The composition of claim 69, wherein the pericyte markers comprise CD146, Nestin, and PDGFRβ.

### Claim 72 (depends on 63)

The composition of claim 63, wherein the cells produce pro-angiogenic paracrine factors.

### Claim 73 (depends on 63)

A method of treating a patient in need thereof comprising administering a therapeutically effective amount of a composition of claim 63 to the patient.

### Claim 74 (depends on 73)

The method of claim 73, wherein the patient has a cardiovascular disease, is receiving vascular grafts, has ischemia, is wound healing, has peripheral ischemia, or has peripheral vascular disease.

### Claim 75 (depends on 73)

The method of claim 73, wherein administering comprises injecting or implanting the cells into the patient.

### Claim 76

A composition comprising mesenchymal stem cells (MSCs) having a combined pericyte/endothelial phenotype for use in the treatment of a patient.

### Claim 77 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 63, 76)

The composition for use of claim 76, wherein the mesenchymal stem cells (MSCs) having a combined pericyte/endothelial phenotype are mesenchymal stem cells (MSCs) having a combined pericyte/endothelial phenotype of any one of claim 26-35 or 63.

### Claim 78 (depends on 76)

The composition for use of claim 76, wherein the patient has a cardiovascular disease, is receiving vascular grafts, has ischemia, is wound healing, has peripheral ischemia, or has peripheral vascular disease.

### Claim 79 (depends on 76)

The composition for use of claim 76, wherein the composition is formulated for injection or implantation into the patient.

### Claim 80

Use of mesenchymal stem cells (MSCs) having a combined pericyte/endothelial phenotype in the manufacture of a medicament for the treatment of a disease in a patient.
